Guidant Delves Back Into Contak CD Data To Answer Panel Concerns
This article was originally published in The Gray Sheet
Executive Summary
Guidant's resubmission of data for its Contak CD PMA will address the concerns of the Circulatory System Devices Panel, which criticized the firm's statistical analysis of trial data at a July 10 meeting.
You may also be interested in...
Guidant Solution To Panel Dilemma Will Not Require New Contak Implants
Guidant's Contak CD "continued access policy" IDE could augment the company's pivotal trial and allow the firm to avoid returning for a second review by the Circulatory System Devices Panel.
Abdominal Aortic Aneurysm Endograft Labeling Changes Likely - DCRD
Updates on long-term clinical data will provide a basis for abdominal aortic aneurysm endovascular graft labeling changes, FDA suggested during a session on the devices July 9 at FDA's Circulatory System Devices Panel meeting in Gaithersburg, Maryland.
FDA, Advisory Panel Agree: Post-Hoc Analyses Won't Fly
CDRH's critique of Guidant's post-hoc analysis of its Contak CD data sends a clear warning to sponsors who attempt to draw positive conclusions about one subgroup from an inconclusive clinical trial.